Using this approach (Figure 3A), miR-4666-3p was predicted to target various cancer-related signaling pathways, including the TGF-β, mitogen-activated protein kinase (MAPK) and insulin signaling pathways, which comprised 33 target genes. This evidence concerns the gene TGFB1 and cancer.